Advertisement
New Zealand markets closed
  • NZX 50

    11,796.21
    -39.83 (-0.34%)
     
  • NZD/USD

    0.5887
    -0.0019 (-0.32%)
     
  • NZD/EUR

    0.5522
    -0.0022 (-0.40%)
     
  • ALL ORDS

    7,817.40
    -81.50 (-1.03%)
     
  • ASX 200

    7,567.30
    -74.80 (-0.98%)
     
  • OIL

    81.96
    -0.77 (-0.93%)
     
  • GOLD

    2,390.30
    -7.70 (-0.32%)
     
  • NASDAQ

    17,394.31
    -99.31 (-0.57%)
     
  • FTSE

    7,837.10
    -39.95 (-0.51%)
     
  • Dow Jones

    37,775.38
    +22.07 (+0.06%)
     
  • DAX

    17,719.82
    -117.58 (-0.66%)
     
  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     
  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     
  • NZD/JPY

    90.9910
    -0.2630 (-0.29%)
     

3 Reasons to Buy AbbVie and 2 Reasons Not to Buy

3 Reasons to Buy AbbVie and 2 Reasons Not to Buy

2023 is expected to be an important year for AbbVie (NYSE: ABBV). The pharmaceutical company is facing its first biosimilar competition in the United States. It's big news because it involves AbbVie's monoclonal antibody blockbuster therapy, Humira, which is on track to generate a second consecutive year of $20 billion-plus in revenue in 2022.